Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, AbbVie, Takeda, Huadong Medicine 
Welcome,         Profile    Billing    Logout  

17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elahere (mirvetuximab soravtansine-gynx) / AbbVie
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Hourglass Jan 2023 - Mar 2023 : Top-line data from MIRASOL trial for high-grade epithelial ovarian cancer
Hourglass Jul 2022 - Sep 2022 : Approval for high-grade epithelial ovarian cancer (based on MIRASOL trial)
Active, not recruiting
3
453
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
ImmunoGen, Inc., Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
09/23
04/24
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
ImmunoGen, Inc., GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
2021-003592-34: c Un estudio para probar mirvetuximab soravtansina en mujeres con cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio sensibles al platino.

Not yet recruiting
2
75
Europe
mirvetuximab soravtansine, IMGN853, Concentrate for solution for injection/infusion, Pred Forte
ImmunoGen, Inc., IMMUNOGEN, INC., ImmunoGen, Inc.
Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio recurrentes, sensibles al platino y con alta expresión del receptor de folatos alfa, Cancer of ovary and related organs Cáncer de ovario y órganos afines, Diseases [C] - Cancer [C04]
 
 
NCT03835819: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruiting
2
18
US
Pembrolizumab, Keytruda, IMGN853, Mirvetuximab soravtansine, Elahere
Dana-Farber Cancer Institute, ImmunoGen, Inc., Merck Sharp & Dohme LLC
Endometrial Cancer
08/25
08/28
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
 
 
MIROVA, NCT04274426: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Active, not recruiting
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
ImmunoGen, Inc.
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05456685: IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
114
Europe, Canada, US, RoW
Mirvetuximab soravtansine, IMGN853, MIRV, Carboplatin
ImmunoGen, Inc.
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
12/26
NCT06365853: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Not yet recruiting
2
100
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, IMGN853, MIRV, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
ImmunoGen, Inc.
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
05/26
05/27
NCT05887609: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Recruiting
2
53
US
Mirvetuximab Soravtansine, IMGN853, MIRV, Olaparib
University of Colorado, Denver, ImmunoGen, Inc.
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/26
12/27
NCT04606914: Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
2
70
US
mirvetuximab soravtansine (MIRV; IMGN853)
University of Alabama at Birmingham
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
05/26
05/28
TAK-853-1501, NCT06390995: A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Recruiting
1/2
25
Japan
TAK-853, Mirvetuximab Soravtansine
Takeda
Ovarian Cancer, Solid Tumors
09/25
09/26
NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
1
25
US
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate
Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc.
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
06/22
12/23
NCI-2016-01913, NCT02996825: Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Completed
1
44
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
02/24
02/24
NCT05483933: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
07/24
04/25

Download Options